Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2000-06-16
Target enrollment:
Participant gender:
Summary
Current therapies for Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's
Lymphoma provide very limited benefit to the patient. The anti-cancer properties of
Antineoplaston therapy suggest that it may prove beneficial in the treatment of Refractory or
Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Refractory or Recurrent Intermediate-Grade Stage
II - IV Non-Hodgkin's Lymphoma.